A Placebo and Active Controlled Study of ONO-6950 Following Allergen Challenge in Patients With Asthma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objectives are
- to determine the effect of ONO-6950 200 mg QD versus placebo administered for 8 days on
early asthmatic response (EAR) and late asthmatic response (LAR) induced by inhaled
allergen
- to determine the safety and tolerability of ONO-6950 200 mg QD administered for 8 days
in patients with asthma
The secondary objectives are:
- to compare the effect of ONO-6950 versus montelukast on the % decrease of FEV1 following
allergen exposure, and
- to determine the effect of ONO-6950 versus placebo and montelukast on allergen-induced
airway hyperresponsiveness (AHR) as measured by methacholine challenge